• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲氨蝶呤对大鼠的慢性毒性:胆碱对肝脏的部分至完全保护作用:简报

Chronic toxicity of methotrexate in rats: partial to complete projection of the liver by choline: Brief communication.

作者信息

Freeman-Narrod M, Narrod S A, Custer R P

出版信息

J Natl Cancer Inst. 1977 Sep;59(3):1013-7. doi: 10.1093/jnci/59.3.1013.

DOI:10.1093/jnci/59.3.1013
PMID:894741
Abstract

Methotrexate (MTX) inhibits the enzyme dihydrofolate reductase, which in turn limits the body's ability to perform transmethylation reactions. This study examined the hypothesis that the consequent deficiency of an important methylated compound, choline, may have contributed to the MTX-induced fatty change in the liver of W rats. Groups of rats were given MTX alone or MTX plus choline in varying dose combinations. All groups but one receiving the combined treatment showed a significantly lower triglyceride concentration in their livers and much less visible hepatocytic fat on histologic examination than did those given MTX alone. The protective effect of choline on the liver was dose related, the unaffected group having received a very small amount. Growth rate, survival, and hematopoietic depression due to MTX were unaltered by choline administration.

摘要

甲氨蝶呤(MTX)可抑制二氢叶酸还原酶,进而限制机体进行转甲基反应的能力。本研究检验了这样一个假设,即重要的甲基化化合物胆碱的缺乏可能导致了MTX诱导的W大鼠肝脏脂肪变性。将大鼠分组,分别给予单独的MTX或MTX与胆碱的不同剂量组合。除一组接受联合治疗外,所有接受联合治疗的组肝脏中的甘油三酯浓度均显著低于单独给予MTX的组,并且在组织学检查中可见的肝细胞脂肪也少得多。胆碱对肝脏的保护作用与剂量相关,未受影响的组接受的胆碱量非常少。给予胆碱不会改变MTX所致的生长速率、生存率和造血抑制。

相似文献

1
Chronic toxicity of methotrexate in rats: partial to complete projection of the liver by choline: Brief communication.甲氨蝶呤对大鼠的慢性毒性:胆碱对肝脏的部分至完全保护作用:简报
J Natl Cancer Inst. 1977 Sep;59(3):1013-7. doi: 10.1093/jnci/59.3.1013.
2
Methotrexate effects on hepatic betaine levels in choline-supplemented and choline-deficient rats.甲氨蝶呤对补充胆碱和缺乏胆碱的大鼠肝脏甜菜碱水平的影响。
Drug Nutr Interact. 1982;1(4):275-8.
3
Choline deficiency and methotrexate treatment induces marked but reversible changes in hepatic folate concentrations, serum homocysteine and DNA methylation rates in rats.胆碱缺乏和甲氨蝶呤治疗会在大鼠肝脏叶酸浓度、血清同型半胱氨酸及DNA甲基化率方面引发显著但可逆的变化。
J Am Coll Nutr. 1995 Oct;14(5):480-5. doi: 10.1080/07315724.1995.10718539.
4
Procarbazine carcinogenicity in methotrexate-treated or lipotrope-deficient male rats.
Carcinogenesis. 1990 Sep;11(9):1491-5. doi: 10.1093/carcin/11.9.1491.
5
Effects of choline deficiency and methotrexate treatment upon liver folate content and distribution.胆碱缺乏和甲氨蝶呤治疗对肝脏叶酸含量及分布的影响。
Cancer Res. 1991 Jan 1;51(1):16-21.
6
Choline antagonism of methotrexate liver toxicity in the rat.
Med Pediatr Oncol. 1977;3(1):9-14. doi: 10.1002/mpo.2950030103.
7
Brain folates and DNA methylation in rats fed a choline deficient diet or treated with low doses of methotrexate.
Int J Vitam Nutr Res. 1996;66(3):232-6.
8
A one-month repeated oral dose toxicity study of methotrexate in unilaterally nephrectomized rats.甲氨蝶呤对单侧肾切除大鼠的为期一个月的重复口服剂量毒性研究。
J Toxicol Sci. 1998 Nov;23 Suppl 5:681-99. doi: 10.2131/jts.23.supplementv_681.
9
Toxicity of methotrexate in rats preexposed to nitrous oxide.预先暴露于一氧化二氮的大鼠中氨甲蝶呤的毒性
Cancer Res. 1989 Nov 15;49(22):6337-41.
10
Hepatotoxicity in Wistar rats following chronic methotrexate administration: a model of human reaction.
J Natl Cancer Inst. 1977 Apr;58(4):1011-7. doi: 10.1093/jnci/58.4.1011.

引用本文的文献

1
The Shuttling of Methyl Groups Between Folate and Choline Pathways.甲基在叶酸和胆碱代谢途径之间的穿梭
Nutrients. 2025 Jul 30;17(15):2495. doi: 10.3390/nu17152495.
2
Effect of methotrexate on homocysteine and other sulfur compounds in tissues of rats fed a normal or a defined, choline-deficient diet.甲氨蝶呤对喂食正常或特定胆碱缺乏饮食的大鼠组织中同型半胱氨酸及其他硫化合物的影响。
Cancer Chemother Pharmacol. 1988;21(4):313-8. doi: 10.1007/BF00264197.